These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19345749)

  • 1. The effects of long-term raloxifene and estradiol treatments on bone in a patient with congenital aromatase deficiency.
    Zirilli L; Maffei L; Meunier PJ; Chavassieux P; Carani C; Rochira V
    Bone; 2009 Nov; 45(5):827-32. PubMed ID: 19345749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel mutation in the human aromatase gene: insights on the relationship among serum estradiol, longitudinal growth and bone mineral density in an adult man under estrogen replacement treatment.
    Lanfranco F; Zirilli L; Baldi M; Pignatti E; Corneli G; Ghigo E; Aimaretti G; Carani C; Rochira V
    Bone; 2008 Sep; 43(3):628-35. PubMed ID: 18590994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen replacement therapy in a man with congenital aromatase deficiency: effects of different doses of transdermal estradiol on bone mineral density and hormonal parameters.
    Rochira V; Faustini-Fustini M; Balestrieri A; Carani C
    J Clin Endocrinol Metab; 2000 May; 85(5):1841-5. PubMed ID: 10843162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal effects of long-term estrogen and testosterone replacement treatment in a man with congenital aromatase deficiency: evidences of a priming effect of estrogen for sex steroids action on bone.
    Rochira V; Zirilli L; Madeo B; Aranda C; Caffagni G; Fabre B; Montangero VE; Roldan EJ; Maffei L; Carani C
    Bone; 2007 Jun; 40(6):1662-8. PubMed ID: 17400043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous estrogen levels and the effects of ultra-low-dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal women.
    Huang AJ; Ettinger B; Vittinghoff E; Ensrud KE; Johnson KC; Cummings SR
    J Bone Miner Res; 2007 Nov; 22(11):1791-7. PubMed ID: 17620054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age.
    Van Pottelbergh I; Goemaere S; Kaufman JM
    J Clin Endocrinol Metab; 2003 Jul; 88(7):3075-81. PubMed ID: 12843146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of estrogen replacement therapy on bone and glucose metabolism in a male with congenital aromatase deficiency.
    Herrmann BL; Janssen OE; Hahn S; Broecker-Preuss M; Mann K
    Horm Metab Res; 2005 Mar; 37(3):178-83. PubMed ID: 15824973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis.
    Hernández E; Valera R; Alonzo E; Bajares-Lilue M; Carlini R; Capriles F; Martinis R; Bellorin-Font E; Weisinger JR
    Kidney Int; 2003 Jun; 63(6):2269-74. PubMed ID: 12753317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of suppression of estrogen action by the p450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys.
    Wickman S; Kajantie E; Dunkel L
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3785-93. PubMed ID: 12915670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypothalamic-pituitary-gonadal axis in two men with aromatase deficiency: evidence that circulating estrogens are required at the hypothalamic level for the integrity of gonadotropin negative feedback.
    Rochira V; Zirilli L; Genazzani AD; Balestrieri A; Aranda C; Fabre B; Antunez P; Diazzi C; Carani C; Maffei L
    Eur J Endocrinol; 2006 Oct; 155(4):513-22. PubMed ID: 16990650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene.
    Herrmann BL; Saller B; Janssen OE; Gocke P; Bockisch A; Sperling H; Mann K; Broecker M
    J Clin Endocrinol Metab; 2002 Dec; 87(12):5476-84. PubMed ID: 12466340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men.
    Doran PM; Riggs BL; Atkinson EJ; Khosla S
    J Bone Miner Res; 2001 Nov; 16(11):2118-25. PubMed ID: 11697809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of estrogen replacement throughout childhood on growth, pituitary-gonadal axis and bone in a 46,XX patient with CYP19A1 deficiency.
    Janner M; Flück CE; Mullis PE
    Horm Res Paediatr; 2012; 78(4):261-8. PubMed ID: 22964562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose transdermal estradiol induces breast density and heterogeneity changes comparable to those of raloxifene.
    Nielsen M; Raundahl J; Pettersen PC; Loog M; Karemore G; Karsdal MA; Christiansen C
    Menopause; 2009; 16(4):785-91. PubMed ID: 19322115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography.
    Genant HK; Lang T; Fuerst T; Pinette KV; Zhou C; Thiebaud D; Diez-Perez A
    Bone; 2004 Nov; 35(5):1164-8. PubMed ID: 15542042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
    Dane C; Dane B; Cetin A; Erginbas M
    Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk.
    Sarkar S; Reginster JY; Crans GG; Diez-Perez A; Pinette KV; Delmas PD
    J Bone Miner Res; 2004 Mar; 19(3):394-401. PubMed ID: 15040827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accretion of bone mass and strength with parathyroid hormone prior to the onset of estrogen deficiency can provide temporary beneficial effects in skeletally mature rats.
    Shen V; Birchman R; Liang XG; Wu DD; Dempster DW; Lindsay R
    J Bone Miner Res; 1998 May; 13(5):883-90. PubMed ID: 9610753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pituitary function in a man with congenital aromatase deficiency: effect of different doses of transdermal E2 on basal and stimulated pituitary hormones.
    Rochira V; Balestrieri A; Faustini-Fustini M; Borgato S; Beck-Peccoz P; Carani C
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2857-62. PubMed ID: 12050263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B; San Martin J; Crans G; Pavo I
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.